Pamela Blair Allen, MD, MSc

One star
One star
One star
One star
One half star

Rating: 4.8 out of 5 (67 ratings)

Role

Hematology Oncology
Specialty

Lymphoma
Research Program

Cancer Prevention and Control
Practicing Since

2017

Call 404-778-0519

Background

A board certified hematologist, Pamela Blair Allen, MD, MSc, specializes in the treatment of hematological malignancies and treats patients at Winship Cancer Institute of Emory University (Clifton campus). She is an attending physician in the Bone Marrow and Stem Cell Transplant Center at Winship Cancer Institute.

Dr. Allen is an associate professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine. Prior to joining the faculty at Emory in 2017, Dr. Allen was a medical oncology fellow at Northwestern University in Chicago, Illinois.

See Dr. Allen's publications here.

Titles & Roles

Associate Professor, Department of Hematology and Medical Oncology

Emory University School of Medicine

Education & Training

Education

Fellowship, Hematology & Oncology, 2017
Northwestern Memorial Hospital
Professional Education, MS, 2017
Northwestern University
Residency, Internal Medicine, 2017
University of Maryland
Medical Education, MD, 2010
University of Florida

Board Certifications

Medical Oncology
American Board of Internal Medicine, 2017
Hematology
American Board of Internal Medicine, 2017
Internal Medicine
American Board of Internal Medicine, 2013

Professional Memberships

American Society of Hematology
American Society of Clinical Oncology
Lymphoma Research Foundation and Society for Immunotherapy of Cancer
Cutaneous Lymphoma Foundation

Research

Clinical Trials

Dr. Allen is the principal investigator of clinical trials evaluating novel agents for patients with recurrent or relapsed lymphoma.

View Current Clinical Trials


Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma Phase II Conditions Nodular Lymphocyte Predominant B-Cell Lymphoma, Recurrent Nodular Lymphocyte Predominant B-Cell Lymphoma, Refractory Nodular Lymphocyte Predominant B-Cell Lymphoma Location Winship Cancer Institute
Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma Phase I Conditions Relapsed or Refractory T Cell Lymphoma Location Winship Cancer Institute
AHOD2131 Phase III Location Emory Saint Joseph's Hospital, Emory Proton Therapy Center, Winship Cancer Institute
Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma Phase II Conditions Angioimmunoblastic T-cell Lymphoma, Enteropathy-Associated T-Cell Lymphoma, Follicular T-Cell Lymphoma, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype, Peripheral T-Cell Lymphoma, Not Otherwise Specified Location Grady Health System, Winship Cancer Institute
Nonconforming Lisocabtagene Maraleucel Expanded Access Protocol Phase Expanded Access Conditions Lymphoma, Large B-Cell, Diffuse Location Emory University Hospital Midtown, Winship Cancer Institute
Phase N/A Location Winship Cancer Institute

Publications

Title/Journal	Authors	Publication Date
ASTCT and USCLC Clinical Practice Recommendations for Allogeneic Stem Cell Transplant in Mycosis Fungoides and Sézary Syndrome. Journal of the American Academy of Dermatology	A Goyal, D O'Leary, B Dabaja, WK Weng, J Zain, C Cutler, J Guitart, YH Kim, LJ Geskin, RT Hoppe, LD Wilson, AW Beaven, S Horwitz, PB Allen, SK Barta, K Bohjanen, JE Brammer, JB Carter, N Comfere, JA DeSimone, K Dusenbery, M Duvic, A Huen, D Jagadeesh, CR Kelsey, MS Khodadoust, MJ Lechowicz, N Mehta-Shah, AJ Moskowitz, EA Olsen, C Poh, B Pro, C Querfeld, C Sauter, L Sokol, O Sokumbi, RA Wilcox, JA Zic, A Gru, M Hamadani, F Foss	04/06/2025
Efficacy and Safety of Denileukin Diftitox-Cxdl, an Improved Purity Formulation of Denileukin Diftitox, in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	FM Foss, YH Kim, HM Prince, OE Akilov, C Querfeld, L Seminario-Vidal, DC Fisher, TM Kuzel, CK Yannakou, LJ Geskin, T Feldman, L Sokol, PB Allen, NH Dang, F Cabanillas, HK Wong, CE Ooi, D Xing, N Sauter, P Singh, M Czuczman, M Duvic	04/01/2025
Advances in Novel Systemic Therapies for the Management of Cutaneous T Cell Lymphoma (CTCL). Current hematologic malignancy reports	KB Case, PB Allen	01/13/2025
Atezolizumab combined with immunogenic salvage chemoimmunotherapy in patients with transformed diffuse large B-cell lymphoma. Haematologica	T Othman, P Frankel, P Allen, LL Popplewell, G Shouse, T Siddiqi, AV Danilov, N Ruel, S Daniels, L Peters, S Khoo, ST Rosen, E Sharon, M Villalona-Calero, C Ruel, J Tuscano, AF Herrera	01/01/2025
Fifteen-Year Experience of a Single Institution: Outcomes for Early-Stage Hodgkins Lymphoma Comparing Chemotherapy Alone Versus Combined Modality Therapy. Advances in radiation oncology	JY Qian, R Amin, H Ali, Y Cao, JM Switchenko, AS Rashid, PB Allen, S Hanasoge, MK Khan	12/01/2024
Valemetostat monotherapy in patients with relapsed or refractory non-Hodgkin lymphoma: a first-in-human, multicentre, open-label, single-arm, phase 1 study. The Lancet. Oncology	D Maruyama, E Jacobsen, P Porcu, P Allen, K Ishitsuka, S Kusumoto, T Narita, K Tobinai, F Foss, K Tsukasaki, T Feldman, Y Imaizumi, K Izutsu, S Morishima, N Yamauchi, J Yuda, JE Brammer, T Kawamata, J Ruan, K Nosaka, A Utsunomiya, J Wang, J Zain, Y Kakurai, H Yamauchi, Y Hizukuri, N Biserna, M Tachibana, A Inoue, SM Horwitz	12/01/2024
ASTCT and USCLC Clinical Practice Recommendations for Allogeneic Stem Cell Transplant in Mycosis Fungoides and Sézary Syndrome. Transplantation and cellular therapy	A Goyal, D O'Leary, B Dabaja, WK Weng, J Zain, C Cutler, J Guitart, YH Kim, LJ Geskin, RT Hoppe, LD Wilson, AW Beaven, S Horwitz, PB Allen, SK Barta, K Bohjanen, JE Brammer, JB Carter, N Comfere, JA DeSimone, K Dusenbery, M Duvic, A Huen, D Jagadeesh, CR Kelsey, MS Khodadoust, MJ Lechowicz, N Mehta-Shah, AJ Moskowitz, EA Olsen, C Poh, B Pro, C Querfeld, C Sauter, L Sokol, O Sokumbi, RA Wilcox, JA Zic, M Hamadani, F Foss	11/01/2024
The CNS relapse in T-cell lymphoma index predicts CNS relapse in patients with T- and NK-cell lymphomas. Blood advances	RS Bhansali, F Ellin, T Relander, M Cao, W Li, Q Long, N Ganesan, R Stuver, SM Horwitz, K Wudhikarn, SR Hwang, NN Bennani, J Chavez, L Sokol, H Saeed, F Duan, P Porcu, P Pullarkat, N Mehta-Shah, JM Zain, M Ruiz, JE Brammer, R Prakash, SP Iyer, AJ Olszewski, A Major, PA Riedell, SM Smith, C Goldin, B Haverkos, B Hu, TZ Zhuang, PB Allen, W Toama, M Janakiram, TR Brooks, D Jagadeesh, N Hariharan, AM Goodman, G Hartman, P Ghione, F Fayyaz, JM Rhodes, EA Chong, JN Gerson, DJ Landsburg, SD Nasta, SJ Schuster, J Svoboda, M Jerkeman, SK Barta	07/09/2024
Paradigm Shifts in Hodgkin Lymphoma Treatment: From Frontline Therapies to Relapsed Disease. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting	C Burton, P Allen, AF Herrera	06/01/2024
Subsequent malignant neoplasms in patients previously treated with anti-CD19 CAR T-cell therapy. Blood advances	M Melody, N Epperla, G Shouse, J Romancik, P Allen, TK Moyo, V Kenkre, T Ollila, L Fitzgerald, B Hess, K David, MM Herr, O Odetola, A Lin, J Moreira, S Ma, JN Winter, I Roy, D Stephens, A Danilov, NN Shah, SK Barta, M Cortese, JB Cohen, LI Gordon, R Karmali	05/28/2024
EBV-Positive Nodal T- and NK-Cell Lymphoma Mimicking Anaplastic Large Cell Lymphoma: A Case Report. Hematology reports	B Abro, P Allen, S Asakrah, K Bradley, L Zhang	05/23/2024
Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study. The Lancet. Oncology	Y Song, L Malpica, Q Cai, W Zhao, K Zhou, J Wu, H Zhang, N Mehta-Shah, K Ding, Y Liu, Z Li, L Zhang, M Zheng, J Jin, H Yang, Y Shuang, DH Yoon, S Gao, W Li, Z Zhai, L Zou, Y Xi, Y Koh, F Li, M Prince, H Zhou, L Lin, H Liu, P Allen, F Roncolato, Z Yang, WS Kim, J Zhu	01/01/2024
Impact of cumulative dose of brentuximab vedotin on outcomes of frontline therapy for advanced-stage Hodgkin lymphoma. Blood advances	RE Steiner, SR Hwang, A Khurana, TM Habermann, N Epperla, K Annunzio, PB Allen, K Baird, D Paulino, JP Alderuccio, IS Lossos, K David, AM Evens, K Pandya, SM Bair, M Kamdar, S Ba Aqeel, P Torka, R Lynch, S Smith, L Feng, M Noorani, S Ahmed, R Nair, F Vega, S Wu, P Fang, CC Pinnix, JR Gunther, BS Dabaja, HJ Lee	12/26/2023
Cutaneous T-cell lymphoma with CNS involvement: a case series and review of the literature. CNS oncology	JD Preston, CS Jansen, S Kosaraju, T Niyogusaba, TZ Zhuang, SW Iwamoto, SK Hutto, MJ Lechowicz, PB Allen	12/01/2023
Characterizing Outcomes in Visceral Cutaneous T-Cell Lymphoma: A Single Center Retrospective Study. Clinical lymphoma, myeloma & leukemia	TZ Zhuang, A McCook-Veal, J Switchenko, T Niyogusaba, ES Tarabadkar, K Baird, C O'Leary, D Paulino, MJ Lechowicz, PB Allen	09/01/2023
DMF in CTCL: where do we go from here? Blood	PB Allen	08/31/2023
Sequential pembrolizumab and AVD are highly effective at any PD-L1 expression level in untreated Hodgkin lymphoma. Blood advances	PB Allen, X Lu, Q Chen, K O'Shea, JS Chmiel, LB Slonim, M Sukhanova, H Savas, AM Evens, R Advani, B Pro, R Karmali, B Palmer, RA Bayer, RM Eisner, E Mou, G Dillehay, LI Gordon, JN Winter	06/27/2023
Low neutralizing activity of AZD7442 against current SARS-CoV-2 Omicron variants in patients with B-cell malignancies. Blood advances	A Chang, JL Koff, L Lai, VM Orellana-Noia, M Surati, AMK Leal, ML Ellis, B Wali, A Moreno, SL Linderman, CB O'Leary, PB Allen, MC Churnetski, MV Dhodapkar, MS Suthar, JB Cohen, R Ahmed	06/13/2023
Pembrolizumab Added to Ifosfamide, Carboplatin, and Etoposide Chemotherapy for Relapsed or Refractory Classic Hodgkin Lymphoma: A Multi-institutional Phase 2 Investigator-Initiated Nonrandomized Clinical Trial. JAMA oncology	LJ Bryan, C Casulo, PB Allen, SE Smith, H Savas, GL Dillehay, R Karmali, B Pro, KL Kane, LA Bazzi, JS Chmiel, BA Palmer, J Mehta, LI Gordon, JN Winter	05/01/2023
Mitigation strategies among cutaneous T-cell lymphoma patients with positive Staphylococcus aureus skin and soft tissue cultures have unclear impacts on the risk of subsequent bacteremia. Leukemia & lymphoma	PB Allen, S Goyal, J Switchenko, E Tarabadkar, S Pouch, P Parikh, A Palmer, D Martini, E Kim, MJ Lechowicz	03/01/2023
Staging lymph nodes and blood at diagnosis in mycosis fungoides identifies patients at increased risk of progression to advanced stage: A retrospective cohort study. Cancer	PB Allen, AA McCook-Veal, JM Switchenko, DM Paulino, T Niyogusaba, KM Baird, ES Tarabadkar, MJ Lechowicz	02/15/2023
Antibody binding and neutralization of live SARS-CoV-2 variants including BA.4/5 following booster vaccination of patients with B-cell malignancies. Cancer research communications	A Chang, A Akhtar, L Lai, VM Orellana-Noia, SL Linderman, AA McCook-Veal, JM Switchenko, M Saini, RM Valanparambil, KA Blum, PB Allen, MJ Lechowicz, JT Romancik, A Ayers, A Leal, CB O'Leary, MC Churnetski, K Baird, M Kives, J Wrammert, AK Nooka, JL Koff, MV Dhodapkar, MS Suthar, JB Cohen, R Ahmed	12/01/2022
Ixazomib With or Without Rituximab Following Maintenance Autologous Stem Cell Transplant in Mantle Cell Lymphoma: A Single-Center Phase I Trial. Clinical lymphoma, myeloma & leukemia	JT Romancik, Z Chen, PB Allen, EK Waller, K Valla, A Colbert, C Rosand, AF Palmer, CR Flowers, JB Cohen	12/01/2022
Clinical Presentation and Outcome Differences Between Black Patients and Patients of Other Races and Ethnicities With Mycosis Fungoides and Sézary Syndrome. JAMA dermatology	PB Allen, S Goyal, T Niyogusaba, C O'Leary, A Ayers, ES Tarabadkar, MK Khan, MJ Lechowicz	11/01/2022
CLL-515 Antibody Responses Against SARS-CoV-2 Variants after Booster Vaccination in Patients With B Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia. Clinical lymphoma, myeloma & leukemia	A Chang, L Lai, A Akhtar, S Linderman, V Orellana-Noia, M Saini, R Valanparambil, K Blum, P Allen, M Lechowicz, J Romancik, A Ayers, C O'Leary, M Churnetski, M Kives, A Nooka, J Koff, M Dhodapkar, M Suthar, J Cohen, R Ahmed	09/27/2022
African American and Caucasian patients with Sézary syndrome have no differences in outcomes at an ethnically diverse urban medical center. Leukemia & lymphoma	DJ Martini, S Goyal, JM Switchenko, MJ Lechowicz, PB Allen	09/01/2022
Outcomes Among Classical Hodgkin Lymphoma Patients After an Interim PET Scan: A Real-World Experience. Clinical lymphoma, myeloma & leukemia	MS Hamid, SC Rutherford, H Jang, S Kim, K Patel, NL Bartlett, MK Malecek, MP Watkins, KJ Maddocks, DA Bond, TA Feldman, G Magarelli, RH Advani, MA Spinner, AM Evens, M Shah, S Ahmed, DM Stephens, P Allen, MT Tees, R Karmali, BD Cheson, MS Yazdy, C Strouse, NA Bailey, JM Pagel, R Ramchandren	07/01/2022
Racial differences in clinical presentation and outcomes in mycosis fungoides and Sézary syndrome in the United States: a large singe center retrospective analysis. European journal of cancer (Oxford, England : 1990)	PB Allen, S Goyal, C O'Leary, A Ayers, T Niyogusaba, MK Khan, MJ Lechowicz	10/01/2021
T-Cell Receptor Gene Rearrangement Clonality, Flow Cytometry Status, and Associated Outcomes in Early-Stage Cutaneous T-Cell Lymphoma. JAMA dermatology	JA Marks, JM Switchenko, DJ Martini, ES Tarabadkar, MK Khan, MJ Lechowicz, PB Allen	08/01/2021
Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma. Blood	PB Allen, H Savas, AM Evens, RH Advani, B Palmer, B Pro, R Karmali, E Mou, J Bearden, G Dillehay, RA Bayer, RM Eisner, JS Chmiel, K O'Shea, LI Gordon, JN Winter	03/11/2021
Supporting Decision-Making on Fertility Preservation Among Adolescent and Young Adult Women With Cancer. Oncology (Williston Park, N.Y.)	JB Payne, CR Flowers, PB Allen	11/12/2020
Maintenance Therapy for Cutaneous T-cell Lymphoma After Total Skin Electron Irradiation: Evidence for Improved Overall Survival With Ultraviolet Therapy. Clinical lymphoma, myeloma & leukemia	MR Kudelka, JM Switchenko, MJ Lechowicz, N Esiashvili, CR Flowers, MK Khan, PB Allen	11/01/2020
Risk of bacteremia in patients with cutaneous T-cell lymphoma (CTCL). Leukemia & lymphoma	PB Allen, J Switchenko, A Ayers, E Kim, MJ Lechowicz	11/01/2020
Hepatosplenic T-cell lymphoma: a rare but challenging entity. Blood	B Pro, P Allen, A Behdad	10/29/2020
Diffuse Large B-Cell Lymphoma in the Elderly: Current Approaches. Current oncology reports	P Allen	08/22/2020
A systematic review of therapeutic regimens for older patients with newly diagnosed Hodgkin lymphoma. Leukemia & lymphoma	PB Allen, A Ayers, M Behera, AM Evens, C Flowers	07/01/2020
Clustering of cutaneous T-cell lymphoma is associated with increased levels of the environmental toxins benzene and trichloroethylene in the state of Georgia. Cancer	L Clough, AR Bayakly, KC Ward, MK Khan, SC Chen, MJ Lechowicz, CR Flowers, PB Allen, JM Switchenko	04/15/2020

Awards

American Society of Hematology Clinical Research and Mentoring Program
Cutaneous Lymphoma Society Young Investigator Award
Gold Humanism Society

Ratings & Reviews

Patients who are treated in outpatient and inpatient environments are eligible to receive a survey related to their individual care. Displayed ratings and reviews are displayed for Providers who have received at least 30 returned surveys over a 12-month period and are related to all Care Provider related survey questions. To help our patients better understand our Transparency program (ratings and review), the motivations behind it, how ratings are calculated, why ratings and reviews are not published for every EHC Provider, and how this information can be helpful for our patients, please click here.

4.8	One star One star One star One star One half star	Provider showed concern
4.9	One star One star One star One star One half star	Provider explained things clearly
4.8	One star One star One star One star One half star	Provider discussed treatment options
4.8	One star One star One star One star One half star	Provider included you in decisions
4.8	One star One star One star One star One half star	Likelihood of recommending this provider

View Reviews


One star One star One star One star One star	03/28/2025	Dr. Allen has been with me through thick and thin the last five years. I literally trusted her with my life. She is compassionate and gifted in her field. She takes as much time as I need to get my questions answered, which I appreciate so much.
One star One star One star One star One star	03/05/2025	Dr Allen is knowledgeable, professional and caring. Can't say enough She is exceptional
One star One star One star One star One star	12/13/2024	I have known Dr. Allen for over four years now. She is professional, caring and amazing. It has been a long journey. Wouldn't be here without her.
One star One star One star One star One star	12/10/2024	This was my second appointment with her. Review applies to both visits. Amazing amount of time spent explaining a complicated set of conditions and possible concerns, treatments. Also referred to another specialist. Follow-up clear and concise
One star One star One star One star One star	12/04/2024	Dr Allen was professional and very knowledgeable. Took time to thoroughly explain and answered our questions. We are beyond happy with her care
One star One star One star One star One star	11/22/2024	Dr Allen communicated on my Level and answered MY QUESTIONS.
One star One star One star One star One star	09/04/2024	Dr. Allen always takes time to let me get all my questions out.
One star One star One star One star One star	08/23/2024	Dr. Allen was amazing.
One star One star One star One star One star	08/08/2024	Very, very pleased with all stages of operation at your facility